Literature DB >> 29370028

THROMBOCYTOPENIA AS A RISK FACTOR FOR RETINOPATHY OF PREMATURITY.

Selim Sancak1, Handan H Toptan1, Tulin Gokmen Yildirim1, Guner Karatekin1, Fahri Ovali2.   

Abstract

PURPOSE: To study the association between thrombocytopenia and retinopathy of prematurity (ROP).
METHODS: The case-control study was conducted on preterm newborns with ROP between January 2011 and January 2014, retrospectively. The patients were assigned into two groups: Cases required intervention and controls developed no or Stage I ROP.
RESULTS: Eighty-one premature infants with Type I ROP were enrolled to the study with a mean gestational age of 27.6 ± 2.1 (range: 24-32) weeks and birth weight of 993 ± 292 (range: 560-1,930) g. Mean follow-up time was 38.3 ± 2.7 weeks (min: 32 and max: 46 weeks). Cases were individually matched to a set of controls (1:1 ratio). Thrombocytopenia (<150.000/mm) was seen in 58 (71.6%) of the cases with Type I ROP, whereas only 17 (21%) of the controls had thrombocytopenia (P < 0.001). Logistic regression analysis showed that bronchopulmonary dysplasia and thrombocytopenia were significantly associated with Type I ROP (relative risk [95% confidence interval]: 4.19 [1.47-12] and 6.69 [2.83-15.9], respectively). The thrombocytopenia ratio (P = 0.073), thrombocytopenia 1 week before intervention (P = 0.076) and platelet transfusion ratio (P = 0.062) tended to be higher in Zone I ROP compared with Zone II ROP.
CONCLUSION: In our study, there was a significant association between thrombocytopenia and Type I ROP.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 29370028     DOI: 10.1097/IAE.0000000000002028

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  8 in total

1.  Associations between Red Blood Cell and Platelet Transfusions and Retinopathy of Prematurity.

Authors:  Tobias Hengartner; Mark Adams; Riccardo E Pfister; Diane Snyers; Jane McDougall; Salome Waldvogel; Katrin Held-Egli; Lea Spring; Bjarte Rogdo; Thomas Riedel; Romaine Arlettaz Mieth
Journal:  Neonatology       Date:  2020-12-08       Impact factor: 4.035

2.  The Role of Thrombocyte Parameters in Retinopathy of Prematurity Development.

Authors:  Dilek Özkaya
Journal:  Int J Clin Pract       Date:  2022-01-31       Impact factor: 3.149

3.  Thrombocytopenia is associated with severe retinopathy of prematurity.

Authors:  Bertan Cakir; Raffael Liegl; Gunnel Hellgren; Pia Lundgren; Ye Sun; Susanna Klevebro; Chatarina Löfqvist; Clara Mannheimer; Steve Cho; Alexander Poblete; Rubi Duran; Boubou Hallberg; Jorge Canas; Viola Lorenz; Zhi-Jian Liu; Martha C Sola-Visner; Lois Eh Smith; Ann Hellström
Journal:  JCI Insight       Date:  2018-10-04

4.  Platelet transfusion for neonates with thrombocytopaenia: protocol for a systematic review.

Authors:  Dengjun Liu; Jinlin Wu; Tao Xiong; Yan Yue; Jun Tang
Journal:  BMJ Open       Date:  2020-10-16       Impact factor: 2.692

5.  Severe retinopathy of prematurity is associated with early post-natal low platelet count.

Authors:  Raffaele Parrozzani; Elisabetta Beatrice Nacci; Silvia Bini; Giulia Marchione; Sabrina Salvadori; Daniel Nardo; Edoardo Midena
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379

6.  Comparison of Mean Platelet Counts in Preterm Infants with and without Retinopathy of Prematurity.

Authors:  Zi Di Lim; Edwin Pheng; Evelyn Tai Li Min; Hans Van Rostenberghe; Ismail Shatriah
Journal:  Int J Environ Res Public Health       Date:  2021-04-05       Impact factor: 3.390

7.  Platelet is the early predictor of bronchopulmonary dysplasia in very premature infants: an observational cohort study.

Authors:  Xiaoling Wang; Yan Ma; Shenghui Wang; Wenbin Dong; Xiaoping Lei
Journal:  BMC Pulm Med       Date:  2022-03-27       Impact factor: 3.317

8.  The association of platelet counts with development and treatment for retinopathy of prematurity - is thrombocytopenia a risk factor?

Authors:  Aneta Choręziak; Dawid Szpecht; Anna Chmielarz-Czarnocińska; Irmina Pawłowska; Anna Gotz-Więckowska
Journal:  Arch Med Sci       Date:  2019-05-27       Impact factor: 3.318

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.